Century Therapeutics updates $150,000,000 ATM program

Century Therapeutics, Inc. filed a current report describing updates to its shelf registration and at-the-market equity program.

Rhea-AI Filing Summary

Century Therapeutics, Inc. filed a current report describing updates to its shelf registration and at-the-market equity program. A new Form S-3 shelf registration statement became effective on January 9, 2026, replacing the prior shelf. The company also filed a new prospectus supplement dated March 26, 2026 for its existing at-the-market equity offering program with Cowen and Company, LLC, predecessor to TD Securities (USA) LLC, as sales agent under a July 1, 2022 Sales Agreement. Under this program, the company may issue and sell shares of common stock having an aggregate offering price of up to $150,000,000. It has already sold shares with an aggregate offering price of $18,380,259, leaving up to $131,619,741 of common stock available for future sale under the program.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Century Therapeutics (IPSC) disclose in this 8-K filing?

Century Therapeutics reported that its new Form S-3 shelf registration became effective and that it filed a new prospectus supplement for its at-the-market equity offering program, maintaining the ability to raise capital by selling common stock over time.

How large is Century Therapeutics' at-the-market equity program?

The at-the-market equity program allows Century Therapeutics to issue and sell common stock with an aggregate offering price of up to $150,000,000. This structure provides flexibility to raise funds in smaller increments directly into the market when conditions are favorable.

How much has Century Therapeutics already sold under its ATM program?

Century Therapeutics has sold shares of common stock with an aggregate offering price of $18,380,259 under its at-the-market program. These prior sales reduce the remaining capacity available but demonstrate that the facility has already been used as a funding source.

How much capacity remains on Century Therapeutics' ATM program?

As of the March 26, 2026 prospectus supplement, Century Therapeutics has up to $131,619,741 in aggregate offering price remaining for future sales of common stock under the at-the-market program, providing ongoing access to potential equity capital if the company chooses to use it.

Who is the sales agent for Century Therapeutics' ATM program?

The sales agent is Cowen and Company, LLC, predecessor to TD Securities (USA) LLC, under a Sales Agreement dated July 1, 2022. This firm executes market sales of Century Therapeutics’ common stock under the at-the-market equity program described in the filing.

What legal opinions were filed with Century Therapeutics’ ATM prospectus supplement?

Century Therapeutics filed an opinion from Goodwin Procter LLP as Exhibit 5.1, addressing the validity of the shares offered, and a related consent as Exhibit 23.1. These legal documents support the company’s ability to issue shares under the updated at-the-market program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/26/2026 - 04:42 PM Learn about SEC filing dates

false 0001850119 0001850119 2026-03-26 2026-03-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 26, 2026

Century Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40498		84-2040295
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

25 North 38th Street, 11th Floor Philadelphia, Pennsylvania		19104
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (267) 817-5790

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Exchange on Which Registered
Common Stock, par value $0.0001 per share		IPSC		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On July 10, 2025, Century Therapeutics, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a shelf registration statement on Form S-3 (File No. 333-288616), which became effective on January 9, 2026, and replaced the Company’s previous shelf registration statement on Form S-3 (File No. 333-265975) filed with the SEC on July 1, 2022.

In connection with the effectiveness of the new shelf registration statement, the Company also filed with the SEC a new prospectus supplement (the “Prospectus Supplement”), dated March 26, 2026, with respect to the Company’s existing “at the market” equity offering program (the “ATM Program”), pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $150,000,000, from time to time through with Cowen and Company, LLC, predecessor to TD Securities (USA) LLC, as sales agent (the “Sales Agent”), pursuant to a Sales Agreement, dated July 1, 2022, between the Company and the Sales Agent (the “Sales Agreement”).

The Company has sold shares of its common stock having an aggregate offering price of $18,380,259 under the ATM Program. Accordingly, as of the date of the Prospectus Supplement, shares of common stock having an aggregate offering price of up to $131,619,741 remain available for offer and sale under the ATM Program.

The Sales Agreement is filed as Exhibit 1.1 hereto and is incorporated herein by reference.

In connection with the filing of the Prospectus Supplement, the Company is filing as Exhibit 5.1 hereto the opinion of its counsel, Goodwin Procter LLP, which opinion is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

1.1		Sales Agreement (previously filed as Exhibit 1.2 to the Company’s Registration Statement on Form S-3 on July 1, 2022 and incorporated herein by reference).
5.1		Opinion of Goodwin Procter LLP with respect to the validity of the shares.
23.1		Consent of Goodwin Procter LLP (contained in its opinion filed as Exhibit 5.1 and incorporated herein by reference).
104		Cover Page Interactive Data File

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CENTURY THERAPEUTICS, INC.
	By:	/s/ Brent Pfeiffenberger, PharmD, MBA
	Name:	Brent Pfeiffenberger, PharmD, MBA
	Title:	President and Chief Executive Officer

Date: March 26, 2026

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-5.1 EXHIBIT 5.1 9.0 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB